AbbVie Inc. $ABBV Shares Sold by Lmcg Investments LLC

Lmcg Investments LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,240 shares of the company’s stock after selling 3,007 shares during the period. AbbVie comprises about 1.9% of Lmcg Investments LLC’s holdings, making the stock its 9th largest holding. Lmcg Investments LLC’s holdings in AbbVie were worth $33,166,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ABBV. Vanguard Group Inc. grew its position in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after acquiring an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in AbbVie by 6.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares in the last quarter. Norges Bank purchased a new stake in shares of AbbVie during the 2nd quarter worth about $4,288,200,000. Finally, Raymond James Financial Inc. lifted its holdings in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after buying an additional 2,753,312 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Trading Down 1.1%

ABBV opened at $214.38 on Friday. The stock’s 50 day simple moving average is $226.80 and its 200-day simple moving average is $216.47. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market cap of $378.89 billion, a PE ratio of 162.41, a P/E/G ratio of 0.88 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 524.24%.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of analyst reports. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. upped their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $247.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.